What insurance policy changes affect code R25.9?

There are 4 tracked policy changes affecting code R25.9, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code R25.9?

Payers that have issued tracked updates for code R25.9 include: Aetna.

How do I get notified when code R25.9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code R25.9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code R25.9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

R25.9 Insurance Policy Changes

ICD-10 R25.9 is officially defined as "Unspecified abnormal involuntary movements." code R25.9 is referenced in 4 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R25.9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 28, 2026Medium impact
Motor Cortex Stimulation (CPB 0755, reviewed 2026-10-21)
Aetna's Clinical Policy Bulletin 0755 says Aetna considers motor cortex stimulation experimental, investigational, or unproven for the listed indications because its effectiveness has not been established. The listed indications include amyotrophic lateral sclerosis, autism spectrum disorder, cerebral palsy, chronic refractory pain, depression, dysphagia, Parkinson's disease, post-stroke aphasia, post-stroke hemiparesis, seizures, traumatic brain injury and obsessive compulsive disorder, and the bulletin says that list is not all-inclusive. The bulletin also lists CPT, HCPCS and ICD-10 codes that are not covered for the indications listed in the policy.
Aetna · Identified Aug 17, 2026Medium impact
Motor Cortex Stimulation (CPB 0755, reviewed 2026-02-24)
Aetna's Clinical Policy Bulletin 0755 on motor cortex stimulation, with a policy history last review of 10/21/2026, considers motor cortex stimulation experimental, investigational or unproven for many indications because its effectiveness has not been established. The list includes amyotrophic lateral sclerosis, autism spectrum disorder, cerebral palsy, chronic refractory pain (such as central pain syndromes, complex regional pain syndrome, phantom limb pain, thalamic pain and trigeminal neuropathic pain), depression, dysphagia, dystonia secondary to a focal basal ganglia lesion, movement disorders, obsessive compulsive disorder, Parkinson's disease, post-stroke aphasia, post-stroke hemiparesis, seizures, traumatic brain injury, and use of motor cortex stimulation during deep brain stimulator implantation. The policy lists CPT codes 61850, 61860, 61885, 61886, 64568, 95961, 95962 and 95970 as not covered for the indications it lists.
Aetna · Identified Aug 16, 2026Medium impact
Spasticity Management (CPB 0362, reviewed 2026-05-26)
Aetna considers neurosurgical procedures medically necessary for refractory spasticity only when the member has good intrinsic lower extremity motor power but is limited in ambulation by spasticity, has the functional capacity and motivation to take part in post-operative rehabilitation, and has tried and failed non-surgical medical management including baclofen or other muscle relaxants. Aetna considers selective posterior rhizotomy experimental, investigational, or unproven when the member has concomitant dystonia or rigidity, profound lower extremity weakness where the spasticity helps the member stand, progressive neurological disorders, choreoathetosis or cerebellar ataxia, severe damage to the basal ganglia, or severe fixed joint deformities or scoliosis. Acupuncture, botulinum toxin, thalamic stimulation, cryoneurolysis, dry needling, extracorporeal shock wave therapy, mirror therapy, pulsed radiofrequency, transcranial direct current stimulation and several other techniques are considered experimental, investigational, or unproven because the effectiveness of these approaches has not been established.
Aetna · Identified Aug 12, 2026Medium impact
Ambulatory Electroencephalography (CPB 0425, reviewed 2026-07-07)
Aetna considers ambulatory EEG, with or without home video monitoring, medically necessary to classify seizure type in members with epilepsy when routine EEG is equivocal, to diagnose a seizure disorder when history, examination and routine EEG do not resolve the diagnostic uncertainty, and to localize the epileptogenic region during pre-surgical evaluation. These indications apply where the member has had a neurologic examination and standard EEG studies within the past 12 months. Combined ambulatory EEG and home-video recording is considered an equally acceptable alternative to ambulatory EEG alone, while ambulatory EEG for all other indications and implantable sub-scalp continuous EEG systems such as Epios and Minder for managing epilepsy are considered experimental, investigational or unproven.

Watch R25.9

Get one email when a payer policy names R25.9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Motor Cortex Stimulation (CPB 0755, reviewed 2026-10-21)

Motor Cortex Stimulation (CPB 0755, reviewed 2026-02-24)

Spasticity Management (CPB 0362, reviewed 2026-05-26)

Ambulatory Electroencephalography (CPB 0425, reviewed 2026-07-07)

What insurance policy changes affect code R25.9?

Which payers have updated policy for code R25.9?

How do I get notified when code R25.9 policy changes?

Why do payers change policies for code R25.9?